Aetna Denied Experimental Treatment? Here's How to Appeal

One of the most frustrating insurance denials is the "experimental or investigational" classification. When Aetna labels your treatment as experimental, the company has decided it lacks sufficient evidence to be considered standard care — regardless of what your physician recommends or what the clinical evidence shows. Aetna's formal Investigational Policy governs these decisions and covers a surprisingly broad range of treatments, including some with FDA approval and growing acceptance in the medical community. If Aetna denied your treatment as experimental or investigational, you have meaningful grounds to challenge that classification — particularly when the treatment has FDA approval, FDA Breakthrough Therapy Designation, or widespread adoption in peer-reviewed clinical guidelines from organizations like NCCN or ASCO.

Why Insurers Deny Claims as Experimental or Investigational

Aetna denies claims as experimental for several recurring reasons:

• Off-label use denials — A drug FDA-approved for one indication prescribed off-label for a related condition where clinical evidence supports use; Aetna may deny even when published literature and the prescribing oncologist support treatment
• FDA Breakthrough Therapy Designation disputed — Aetna is known for denying treatments that have received FDA Breakthrough Therapy Designation on grounds that the designation is not the same as full approval, despite the designation signaling superior clinical evidence
• Outdated CPBs — Aetna's Clinical Policy Bulletins are updated on a rolling schedule and don't always keep pace with rapidly evolving clinical evidence; a treatment standard in clinical practice may still appear investigational in the CPB
• Surgical technique classification — Procedures that have replaced older approaches may still be classified as investigational in Aetna's CPBs even when taught in residency programs
• Combination therapy — Novel combinations of established treatments may be classified as investigational even when each individual component is covered
• State experimental treatment law violations — Several states (California SB 1813, Texas Insurance Code §1369, New York DFS regulations) require coverage of routine costs in clinical trials or treatments with clinical evidence of benefit; these laws may override Aetna's classification
• Mental Health Parity Act (MHPAEA) Explained" class="auto-link">MHPAEA parity violations — If the denied treatment is for a mental health or substance use condition, MHPAEA §1185a's parity requirements apply and Aetna's investigational criteria may not be more restrictive than those applied to analogous medical conditions

How to Appeal

Step 1: Obtain the Denial Letter and Investigational Policy

Request the denial letter, the complete claims file, the specific Aetna Investigational Policy or CPB cited, and the specific factors Aetna relied on in classifying your treatment as experimental. Under ERISA §1133 and ACA §2719, Aetna must provide this information. Download the applicable CPB from aetna.com/cpb.

Step 2: Research FDA and Clinical Evidence

Determine whether your treatment has:

1. Full FDA approval for any indication (even a different one)
2. FDA Breakthrough Therapy, Fast Track, or Accelerated Approval designation
3. Inclusion in NCCN guidelines, AHA guidelines, ASCO recommendations, or other major society guidelines
4. Published phase II or III clinical trial results in high-impact peer-reviewed journals
5. Endorsement from the relevant specialty medical society (APA, AAOS, AHA, ASCO)

Step 3: Gather Your Documentation

• FDA documentation: approval letter, product labeling, or announcement of any expedited designation
• Peer-reviewed clinical literature: published evidence from high-impact journals supporting your specific indication — include clinical trial results, systematic reviews, and meta-analyses
• Medical society guideline endorsement: NCCN guidelines carry significant weight in oncology denials; identify ASCO, AHA, APA, or other society endorsements
• Treating specialist's expert letter rebutting Aetna's investigational classification by citing specific evidence and explaining why the CPB does not reflect current clinical consensus
• State law documentation: your state's experimental treatment coverage statute if applicable (California SB 1813, Texas Insurance Code §1369, etc.)

Step 4: File the Internal Appeal

File within 180 days. For life-threatening conditions, request expedited review — under ACA §2719, Aetna must respond to expedited appeals within 72 hours. Your appeal should directly challenge each factor Aetna cited in classifying the treatment as investigational, with evidence that the factor is satisfied or the classification is factually wrong. Cite ACA §2719 for External Independent Review: Complete Guide" class="auto-link">external review rights and ERISA §1133 if employer-sponsored.

Step 5: Request Peer-to-Peer Review

Have your treating specialist call Aetna's medical director for a peer-to-peer review. The physician's clinical literature review and expert opinion regarding the evidence base for the treatment often changes the outcome, particularly when Aetna's CPB is outdated relative to current clinical practice.

Step 6: Pursue External Review

If the internal appeal fails, pursue external review immediately under ACA §2719. Experimental treatment denials have a notably higher overturn rate at external review when the treatment has FDA support, peer-reviewed literature backing, or medical society endorsement — because the IRO applies current evidence standards, not Aetna's CPB.

What to Include in Your Appeal

• Denial letter with Aetna Investigational Policy or CPB cited
• FDA approval documentation (for any indication) and any expedited designation documentation
• NCCN or other major society guideline endorsement and peer-reviewed clinical trial results
• Treating specialist's letter rebutting each investigational classification factor
• State experimental treatment law documentation if applicable (CA SB 1813, TX §1369)
• Complete claims file requested from Aetna and certified mail receipts

Fight Back With ClaimBack

Aetna's "experimental" classification can be a moving target — treatments denied as investigational two years ago are now standard care. When a treatment has FDA support, peer-reviewed literature backing, and medical society endorsement, Aetna's investigational classification may be factually wrong. ClaimBack helps you build the clinical and legal case against Aetna's investigational denial in 3 minutes. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal